Table 3 Published prospective trials evaluating the resectability rate after first line-chemotherapy in patients with initially unresectable colorectal liver metastases
Auto (year) | No | Treatments | ORR | Resectability rate | Perioperative complications |
|---|---|---|---|---|---|
Wein (2001) [36] | 53 | 5FU/LV | 41% | 11% | Acceptable |
Pozzo (2002) [37] | 40 | 5FU/LV + irinotecan | 47.5% | 32.5% | Acceptable |
Cals (2004) [38] | 34 | 5FU/LV + irinotecan + oxaliplatin | 50% | 15% | Acceptable |
Tourniguand (2004) [19] | 109 | FOLFOX | 54% | 22% | Acceptable |
| Â | 111 | FOLFIRI | 56% | 9% | Acceptable |
Kohne (2005) [39] | 216 | 5FU/LV + irinitecan | 62.2% | 7% | Acceptable |
| Â | 214 | 5FU/LV | 34.4% | 3% | Acceptable |
Ho (2005) [40] | 40 | 5FU/LV/IRI | 55% | 10% | Acceptable |
Seium (2005) [41] | 30 | 5FU/LV + irinotecan + oxaliplatin | 78% | 23% | Hematological+++ |
Alberts (2005) [42] | 42 | FOLFOX | 60% | 40% | Acceptable |
Masi (2006) [43] | 74 | FOLFIRINOX | 72% | 26% | Â |
Ychou (2007) [44] | 34 | FOLFIRINOX | 70.6% | 26.5% | Acceptable Hematological+++ |
Falcone (2007) [21] | 122 | FOLFIRINOX | 60% | 15% | Hematological+++ |
| Â | 122 | FOLFIRI | 34% | 6% | Â |
Skof E (2009) [46] | 41 | XELIRI | 49% | 24% | Equivalent |
| Â | 46 | FOLFIRI | 48% | 24% | Â |
Zhao R (2010) [47] | 48 | XELIRI | 56.3% | 42% | Diarrhea+++ |